Early secukinumab treatment for moderate to severe hidradenitis suppurativa
Part of Infections, Skin clinical trials.
This study looks at people with moderate to severe hidradenitis suppurativa (HS) who start treatment with secukinumab early. It aims to see how well the treatment works and how it affects the condition over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have a diagnosis of hidradenitis suppurativa (HS) — a skin condition that causes painful lumps and boils.
- Your HS must be considered moderate or severe by your doctor.
- You must be starting or have recently started treatment with secukinumab (a medicine that helps reduce inflammation).
- You must have at least one check-up visit 6 or 12 months after starting treatment.
- You cannot have had major HS surgery (like wide excision or STEEP) in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well secukinumab (Cosentyx) works in real life for people with moderate-to-severe hidradenitis suppurativa (HS) in Canada. If you're just starting this treatment, researchers want to track your progress and side effects.
This study tracks how secukinumab (a new medication) works for hidradenitis suppurativa—a painful skin condition with recurring boils and abscesses—in real-world patient care in Italy. Researchers want to understand treatment patterns and outcomes to help improve care for this condition.
This study looks at whether secukinumab (a drug used for hidradenitis suppurativa) affects heart health in people who also have high heart risk or heart plaque. You'd receive the standard care with secukinumab and undergo special heart imaging to see how the drug affects your arteries.
This trial tests a new medicine called HB0043 for people with moderate to severe hidradenitis suppurativa (a skin condition causing painful lumps). It aims to see if the drug is safe and helps reduce symptoms.
This trial tests two medications, secukinumab and tofacitinib, to see which works better for moderate to severe hidradenitis suppurativa (a skin condition causing painful bumps) in Chinese patients. The goal is to find a more effective treatment option.
This study tests an injected drug called siplizumab for people with moderate to severe hidradenitis suppurativa (HS) that hasn't improved with other treatments. The goal is to see if it safely reduces painful bumps and improves your skin condition.
Hear when a new Hidradenitis Suppurativa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.